Fig. 4From: Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysisAssessment of median Overall Survival (mOS) of first-line treatmentBack to article page
